22:17 , May 24, 2019 |  BC Extra  |  Preclinical News

May 24 Preclinical Quick Takes: Baker-Garcia team controls cytokine receptor signaling; plus data from Surface, Innate, Moderna and Lyvgen

Cytokine mimics permit control of dimer receptor signaling  David Baker and Christopher Garcia's University of Washington-Stanford University team has created cytokine mimetics -- symmetric compounds for tunable control of cytokine receptor signaling. In a proof-of-concept...
23:01 , May 22, 2019 |  BC Extra  |  Preclinical News

SR-Tiget-led team boosts ‘don’t eat me’ signals on viral vectors to improve efficacy

Boosting surface levels of a "don't eat me" signal on lentiviral vectors could enable administration of lower gene therapy doses and prevent immune responses by shielding the vectors from phagocytosis. HIV-derived lentiviral gene therapy vectors...
14:22 , May 14, 2019 |  BC Innovations  |  Distillery Therapeutics

Pyridopyrimidine-based inhibitors of the IK-SMU1 interaction for influenza

DISEASE CATEGORY: Infectious disease INDICATION: Influenza virus Cell culture studies identified two pyridopyrimidine-based inhibitors of the IK cytokine-SMU1 interaction that could help treat influenza A virus infection. In silico screening of a small molecule library...
21:32 , May 13, 2019 |  BC Extra  |  Financial News

Philogen bypasses VCs, taps Italian syndicate for €62M to fuel late stage cancer programs

With €62 million ($69.6 million) in series A cash to carry its two late-stage candidates through clinical development, Philogen will soon have to decide whether to rely on additional deals to find commercialization partners, or...
00:09 , May 8, 2019 |  BC Extra  |  Company News

Regeneron falls after reporting EPS below the Street and disclosing patient deaths

Regeneron lost $2.4 billion in market cap Tuesday after reporting 1Q19 EPS well below consensus and disclosing two patient deaths in a Phase I trial evaluating its bispecific mAb targeting CD20 and CD3, REGN1979, in...
19:21 , May 6, 2019 |  BC Innovations  |  Distillery Therapeutics

Butyrate for C. difficile-induced colitis

DISEASE CATEGORY: Gastrointestinal INDICATION: Colitis Cell culture and mouse studies suggest butyrate or promotion of its synthesis could help treat Clostridium difficile -induced colitis. In human colon epithelium cells treated with supernatants from C. difficile...
17:09 , May 3, 2019 |  BC Week In Review  |  Clinical News

GT Biopharma leveraging NK cells to treat HIV

GT Biopharma is expanding its immuno-oncology platform into HIV thanks to work by its partner suggesting the company's TriKE modality could move the needle from life-long therapies to cures. GT Biopharma Inc. (Pink:GTBP) said April...
01:33 , Apr 19, 2019 |  BC Innovations  |  Targets & Mechanisms

The next wave in neurodegeneration expands beyond neurons

Working in the background, while amyloid therapies have floundered, has been a group of companies betting that the immune system can do for neurodegeneration what it is has done for oncology. The first wave of...
21:58 , Apr 17, 2019 |  BC Extra  |  Preclinical News

Salk study unveils LIF's mechanism in form of pancreatic cancer

A new study from Salk Institute for Biological Studies pinpoints new mechanistic details about how LIF promotes pancreatic cancer, providing preclinical support for Northern Biologics' lead candidate. In a Nature paper published Wednesday, Salk's Tony...
00:24 , Apr 12, 2019 |  BC Innovations  |  Product Development

NLRP3 early and often

Inflammasome inhibitors could offer a step change for a slew of inflammatory diseases and pharma is taking notice. Two acquisitions in six months show the first inflammasome target -- NLRP3 -- is gaining momentum, but...